fda approved tirzepatide confirms shortage is still over, gives compounders a grace period FDA approves weight-loss drug Zepbound

This can include the use of GLP-1 medications, which have been shown to promote weight loss and offer additional health benefits such as reduced inflammation, improved glucose control for those with type 2 diabetes, and reduced cardiovascular risk factors

FDA approval for Zepbound (tirzepatide) injection, the first and only obesity treatment of its kind that activates both GIP and GLP-1 hormone receptors Eli Lilly The FDA approved Eli Lilly and Companys Zepbound (tirzepatide) injection, the first and only obesity treatment of its kind that activates both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) hormone receptors

Zepbound has demonstrated potential benefit in reducing apnea-hypopnea index severity in patients with moderate-to-severe obstructive sleep apnea and concurrent obesity

If youre continuing to lose weight, your cravings remain under control, and youre tolerating the medication well, there may not be a reason to rush to a higher dose

Table of Contents: Who is eligible for Tirzepatide for weight loss

Saloni Dattani: Oh, what was it